{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:08:48Z","timestamp":1757700528371},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,12,15]]},"DOI":"10.2169\/internalmedicine.6723-20","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T22:07:05Z","timestamp":1624658825000},"page":"3991-3993","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Experience of Progressive Multifocal Leukoencephalopathy Development during Ofatumumab Therapy for Chronic Lymphocytic Leukemia"],"prefix":"10.2169","volume":"60","author":[{"given":"Yu","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Neurology, Japan Community Health Care Organization Kyushu Hospital, Japan"},{"name":"Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Department of Neurology, Japan Community Health Care Organization Kyushu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japan Community Health Care Organization Kyushu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Nakamichi","sequence":"additional","affiliation":[{"name":"Department of Virology 1, National Institute of Infectious Diseases, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Saijo","sequence":"additional","affiliation":[{"name":"Department of Virology 1, National Institute of Infectious Diseases, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Tateishi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Japan Community Health Care Organization Kyushu Hospital, Japan"},{"name":"Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6: 667-679, 2010.","DOI":"10.1038\/nrneurol.2010.164"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 10: 816-824, 2009.","DOI":"10.1016\/S1470-2045(09)70161-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383: 546-557, 2020.","DOI":"10.1056\/NEJMoa1917246"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Forryan J, Yong J. Rapid cognitive decline in a patient with chronic lymphocytic leukaemia: a case report. J Med Case Rep 14: 39, 2020.","DOI":"10.1186\/s13256-020-2360-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tan CS, Koralnik IJ. Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system. Lancet Neurol 9: 425-437, 2010.","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110: 2924-2930, 2007.","DOI":"10.1182\/blood-2007-02-068999"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12: 59-63, 2017.","DOI":"10.1016\/j.msard.2017.01.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81: 93-111, 1958.","DOI":"10.1093\/brain\/81.1.93"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84: 1068-1074, 2013.","DOI":"10.1136\/jnnp-2013-304897"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88: 1144-1152, 2017.","DOI":"10.1212\/WNL.0000000000003740"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lutz M, Schulze AB, Rebber E, et al. Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. Cancer Res Treat 49: 548-552, 2017.","DOI":"10.4143\/crt.2016.110"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yoshida H, Ohshima K, Toda J, et al. Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation. Int J Hematol 99: 95-99, 2014.","DOI":"10.1007\/s12185-013-1471-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J Clin Neurosci 22: 598-600, 2015.","DOI":"10.1016\/j.jocn.2014.08.016"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/24\/60_6723-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:42:29Z","timestamp":1715143349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/24\/60_6723-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":13,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6723-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"6723-20"}}